DE69527540D1 - Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen - Google Patents

Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen

Info

Publication number
DE69527540D1
DE69527540D1 DE69527540T DE69527540T DE69527540D1 DE 69527540 D1 DE69527540 D1 DE 69527540D1 DE 69527540 T DE69527540 T DE 69527540T DE 69527540 T DE69527540 T DE 69527540T DE 69527540 D1 DE69527540 D1 DE 69527540D1
Authority
DE
Germany
Prior art keywords
receptor
cells
stem cell
cell factor
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527540T
Other languages
English (en)
Other versions
DE69527540T2 (de
Inventor
Tatsutoshi Nakahata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tosoh Corp
Amgen Inc
Original Assignee
Tosoh Corp
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/340,559 external-priority patent/US5610056A/en
Application filed by Tosoh Corp, Amgen Inc filed Critical Tosoh Corp
Publication of DE69527540D1 publication Critical patent/DE69527540D1/de
Application granted granted Critical
Publication of DE69527540T2 publication Critical patent/DE69527540T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69527540T 1994-11-16 1995-11-16 Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen Expired - Fee Related DE69527540T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/340,559 US5610056A (en) 1994-11-16 1994-11-16 Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
US39314695A 1995-02-21 1995-02-21
PCT/US1995/014999 WO1996015230A2 (en) 1994-11-16 1995-11-16 Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells

Publications (2)

Publication Number Publication Date
DE69527540D1 true DE69527540D1 (de) 2002-08-29
DE69527540T2 DE69527540T2 (de) 2003-01-30

Family

ID=26992162

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527540T Expired - Fee Related DE69527540T2 (de) 1994-11-16 1995-11-16 Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen

Country Status (13)

Country Link
US (1) US5861315A (de)
EP (1) EP0793714B1 (de)
JP (1) JP3600244B2 (de)
CN (1) CN1170926C (de)
AT (1) ATE221118T1 (de)
AU (1) AU699479B2 (de)
CA (1) CA2198603C (de)
DE (1) DE69527540T2 (de)
DK (1) DK0793714T3 (de)
ES (1) ES2180665T3 (de)
MX (1) MX9701512A (de)
PT (1) PT793714E (de)
WO (1) WO1996015230A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
JP2004502401A (ja) * 1998-09-18 2004-01-29 マサチューセッツ　インスティテュート　オブ　テクノロジー 哺乳動物細胞の展開及びティシュエンジニアリングのための成長因子及びホルモンの使用
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2322601A1 (de) * 2000-12-06 2011-05-18 Anthrogenesis Corporation Methode zur Isolierung von Plazentastammzellen
KR100973615B1 (ko) 2001-02-14 2010-08-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
NZ541541A (en) 2001-02-14 2007-04-27 Anthrogenesis Corp A composition suitable for transplantation which comprises a population of hematopoietic stem cells comprising placental stem cells that are CD34+ and CD38-
CA2442177A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US20040235160A1 (en) * 2001-08-07 2004-11-25 Mitsuo Nishikawa Process for preparing hematopoietic stem cells
JP4330995B2 (ja) * 2001-11-15 2009-09-16 チルドレンズ メディカル センター コーポレーション 絨毛膜絨毛、羊水、および胎盤からの胎児性幹細胞を単離、増殖、および分化させる方法、ならびにその治療的使用方法
KR20110036114A (ko) * 2002-02-13 2011-04-06 안트로제네시스 코포레이션 산후 포유류 태반으로부터 유래한 배아-유사 줄기 세포와 그 세포를 사용한 용도 및 치료방법
AU2003222043A1 (en) * 2002-03-18 2003-10-08 National Jewish Medical And Research Center Method for production of neutrophils and uses therefor
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
WO2003089619A2 (en) * 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
EP1400587A1 (de) * 2002-09-19 2004-03-24 MainGen Biotechnologie GmbH Verwendung von Fusionspolypeptiden zur Herstellung von pluripotenten nicht embryonalen Stammzellen
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
CA2505534A1 (en) 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
EP1601248A4 (de) * 2003-02-13 2010-01-27 Anthrogenesis Corp Verwendung von nabelschnurblut zur behandlung von subjekten, die an einer krankheit, einem leiden oder einer störung leiden
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
CA2546942A1 (en) * 2003-11-24 2005-06-16 The Rockefeller University A method for isolating a self-renewing, multipotent slow-cycling cell
CA2547570A1 (en) * 2003-12-02 2005-06-23 Celgene Corporation 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
CA2577447C (en) 2004-08-16 2017-08-01 Cellresearch Corporation Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
JP2008531051A (ja) * 2005-02-28 2008-08-14 リジェネテック，インコーポレイテッド すぐに利用できる末梢血由来の細胞物質を提供する方法およびその組成
WO2007005613A2 (en) * 2005-07-01 2007-01-11 Promega Corporation Network of buoyant particles for biomolecule purification
WO2007047468A2 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8030034B2 (en) 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
CA2633775A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
JP5979811B2 (ja) * 2007-02-12 2016-08-31 アンスロジェネシス コーポレーション 胎盤幹細胞を使用した炎症性疾患の治療
KR20090109127A (ko) * 2007-02-12 2009-10-19 안트로제네시스 코포레이션 부착성 태반 줄기세포에서 유래한 간세포와 연골세포 및 ｃｄ34＋, ｃｄ45－ 태반 줄기세포가 농축된 세포군
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
KR101955140B1 (ko) 2007-09-28 2019-03-06 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
KR20170116221A (ko) * 2007-11-07 2017-10-18 안트로제네시스 코포레이션 조산 합병증의 치료에 있어서의 제대혈의 용도
US8222397B2 (en) * 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
ES2336637B1 (es) * 2009-11-02 2011-01-21 Banc De Sang I Teixits Procedimiento parala expansion indiferenciada u orientada a linaje mieloide de celulas madre hematopoyeticas procedentes de sangre de cordonumbilical, sangre periferica movilizada o medula osea.
ES2666746T3 (es) 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
MX357749B (es) 2011-06-01 2018-07-23 Anthrogenesis Corp Tratamiento contra el dolor utilizando células madre placentarias.
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
EP2953635A4 (de) 2013-02-05 2016-10-26 Anthrogenesis Corp Natürliche killerzellen aus plazenta
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
EP3122866B1 (de) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passives ersetzen von medien
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (de) 2016-05-25 2020-01-01 Terumo BCT, Inc. Zellexpansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3750819B2 (ja) * 1992-04-23 2006-03-01 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Ｃ−ｋｉｔ受容体に対するリガンド及びその使用法
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells

Also Published As

Publication number Publication date
AU699479B2 (en) 1998-12-03
JP3600244B2 (ja) 2004-12-15
ATE221118T1 (de) 2002-08-15
US5861315A (en) 1999-01-19
DK0793714T3 (da) 2002-09-02
PT793714E (pt) 2002-12-31
ES2180665T3 (es) 2003-02-16
CN1224461A (zh) 1999-07-28
MX9701512A (es) 1997-05-31
EP0793714A2 (de) 1997-09-10
EP0793714B1 (de) 2002-07-24
CN1170926C (zh) 2004-10-13
DE69527540T2 (de) 2003-01-30
CA2198603A1 (en) 1996-05-23
WO1996015230A2 (en) 1996-05-23
CA2198603C (en) 2000-06-27
WO1996015230A3 (en) 1996-07-11
AU4407396A (en) 1996-06-06
JPH10509040A (ja) 1998-09-08

Similar Documents

Publication Publication Date Title
DE69527540D1 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
ATE252113T1 (de) Verwendung von wnt polypeptiden
EP0442724A3 (en) Modified hil-6
PL309357A1 (en) Pyrolopyrimidines as compounds acting as antagonists of corticotrophin releasing factor
ES2114786A1 (es) Tromboyetina. trombopoyetina recombinante y procedimiento de obtencion.
IL135068A0 (en) Stimulation of hematopoietic cells in vitro
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DE69032963T2 (de) (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE68928710T2 (de) T-Zellen-Wachstumsfaktor
GB9416657D0 (en) T cell activation
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
DE69530676D1 (de) Gleichzeitige Verabreichung von Interleukin 3 Mutantpolypeptiden mit CSF Faktoren für die hematopoietische Multi-Zelllinien Herstellung
DE69428909D1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
ATE227771T1 (de) Pankreatische ribonuclease mutante und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee